Healthcare · Biotech & Pharma
Colossal Biosciences
Austin, USA · Series C
Implied valuation
Probability modeled from funding stage, momentum & liquidity signals.
Valuation Trajectory
Funding-round staircase from founding · log scale. Modeled round ladder anchored to the current valuation — illustrative, not a published figure.
IPO Model Drivers
Why the odds read this way
Factor weights are illustrative decompositions of the modeled IPO probability, not guarantees.
Down-Round Risk
Valuation downside pressure
Mixed signals — limited valuation history with 80% modeled IPO odds keep down-round risk in the middle band.
Asset brief
Colossal Biosciences is a Healthcare · Biotech & Pharma company last marked at $10.32B. Stage: Series C, $380MM raised to date. No verified market-moving events in the last 30 days.
Colossal Biosciences is a biotechnology and genetic engineering company focused on de-extinction and species conservation. The company uses advanced gene-editing technologies, such as CRISPR, with the goal of resurrecting extinct species like the woolly mammoth and the dodo bird, as well as protecting currently endangered species.
Capital Timeline
Funding & liquidity milestones
Series C
$380MM raised · $10.32B